All people who inject drugs should be offered hepatitis C treatment
Evidence supports treatment (pegylated interferon plus ribavirin) of hepatitis C in people who inject drugs, and this high-risk population should be treated regardless of injecting drug status.
Download report
Professor Margaret Hellard AM
For almost two decades Margaret’s work has centred around infectious diseases, preventing their transmission and identifying the impact of these infections in vulnerable populations. A researcher and clinician, her principal research interests are in the epidemiology of blood-borne viruses (BBVs) HIV, hepatitis B and hepatitis C, sexually transmitted infections, and improving the management of individuals who already have the infection.
EMAIL